GDUFA Research Impacting Generic Development, ANDA Approvals
Executive Summary
Increases in approved ANDAs that were affected by GDUFA research shows the importance of the US FDA’s regulatory science program.
You may also be interested in...
US FDA’s New Generics Chief: We Need More Flexibility For Complex Products
Iilun Murphy said Hatch-Waxman was written with immediate-release oral drugs in mind, not the complex generics becoming more popular today. The agency is evaluating the issue.
US FDA’s New Generics Chief: We Need More Flexibility For Complex Products
Iilun Murphy said Hatch-Waxman was written with immediate-release oral drugs in mind, not the complex generics becoming more popular today. The agency is evaluating the issue.
Will US FDA User Fee Deal Allow BsUFA Reg Science Research To Start?
The FDA had picked grantees for the initial round of biosimilar regulatory science research, but told them not to start major activities until the user fee reauthorization was assured. Congress now appears to have reached deal for a ‘practically clean’ reauthorization.